Department of Internal Medicine, Dokuz Eylul University, Izmir, Turkey.
Med Sci Monit. 2010 Jan;16(1):CR41-7.
Paraoxonase-1 (PON-1) may play an important role in atherosclerosis. Atherosclerosis is an inflammatory disease and C-reactive protein is a marker for inflammation. The aim of this study was to determine serum PON-1 activity and high-sensitivity C-reactive protein (hs-CRP) levels and assess carotid intima-media thickness, a marker of early atherosclerotic changes, in patients with subclinical hypothyroidism.
MATERIAL/METHODS: hs-CRP concentrations and PON-1 activity with respect to carotid intima-media thickness were evaluated in 38 subclinical hypothyroidism patients (normolipidemic, mean age: 49.79+/-10.04 years) before and after 3 months of stable euthyroidism and compared with those of 19 euthyroid normolipidemic healthy individuals (mean age: 49.95+/-8.12 years).
At baseline, the patients with subclinical hypothyroidism had similar levels of PON-1 activity and hs-CRP and a similar lipid profile as the controls; however, the carotid intima-media thickness was greater than in the controls. Levothyroxine treatment had no effect on serum PON-1 activity and hs-CRP level, but it resulted in a significant reduction in carotid intima-media thickness in the subclinical hypothyroidism patients.
PON-1 activity and hs-CRP levels did not significantly differ between subclinical hypothyroid patients and controls. Although levothyroxine treatment might have the potential to reverse the progression of atherosclerosis in subclinical hypothyroid patients, PON-1 activity and hs-CRP levels were not affected by this treatment. The reduction in carotid intima-media thickness was independent of the decrease in serum lipid profile or other variables.
对氧磷酶-1(PON-1)可能在动脉粥样硬化中发挥重要作用。动脉粥样硬化是一种炎症性疾病,C 反应蛋白是炎症的标志物。本研究旨在确定亚临床甲状腺功能减退症患者的血清 PON-1 活性和高敏 C 反应蛋白(hs-CRP)水平,并评估颈动脉内膜中层厚度(反映早期动脉粥样硬化变化的标志物)。
材料/方法:评估 38 例亚临床甲状腺功能减退症患者(血脂正常,平均年龄:49.79±10.04 岁)在稳定甲状腺功能正常 3 个月前后的 hs-CRP 浓度和 PON-1 活性与颈动脉内膜中层厚度的关系,并与 19 例血脂正常的健康甲状腺功能正常对照者(平均年龄:49.95±8.12 岁)进行比较。
在基线时,亚临床甲状腺功能减退症患者的 PON-1 活性和 hs-CRP 水平与对照组相似,血脂谱也相似;然而,颈动脉内膜中层厚度大于对照组。左甲状腺素治疗对血清 PON-1 活性和 hs-CRP 水平没有影响,但可使亚临床甲状腺功能减退症患者的颈动脉内膜中层厚度显著降低。
亚临床甲状腺功能减退症患者与对照组的 PON-1 活性和 hs-CRP 水平无显著差异。尽管左甲状腺素治疗可能有逆转亚临床甲状腺功能减退症患者动脉粥样硬化进展的潜力,但 PON-1 活性和 hs-CRP 水平不受这种治疗的影响。颈动脉内膜中层厚度的减少与血清血脂谱或其他变量的降低无关。